[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts into one common share and the award will vest on 09/04/2026 provided Ms. Kwo remains in service through that date. The Form 4 was filed as an individual filing and signed by an attorney-in-fact, Traci S. Umberger, on 09/08/2025. This disclosure reports a non-derivative equity grant to an insider rather than a market sale or open-market purchase; no option exercise, sale price, or cash consideration is reported.

Positive

• 10,909 RSUs granted to Director Elizabeth Kwo, aligning her compensation with shareholder value through equity-based awards
• Clear vesting date: the RSUs vest on 09/04/2026 subject to continued service, providing retention incentives

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A standard director RSU grant tying compensation to continued service and future equity alignment.

The reported transaction is an equity grant of 10,909 RSUs that vests one year after grant subject to continued service. From a governance viewpoint, time‑based RSUs are a common mechanism to align a director's interests with shareholders and to promote retention. The Form 4 filing is routine, disclosing non-derivative beneficial ownership rather than any disposition. The filing provides clear vesting timing but does not disclose grant valuation or relation to total outstanding shares, limiting assessment of dilution or materiality.

Securities Analyst

TL;DR: Non‑derivative RSU award reported; routine disclosure with limited market-impact information.

The transaction code indicates acquisition of RSUs totaling 10,909 units that convert one-for-one into common shares upon vesting on 09/04/2026. Because the Form 4 reports a grant rather than a sale or purchase of existing shares, it does not provide price or proceeds data. The disclosure is useful for tracking insider compensation and future potential share issuance but lacks details on grant value and the company's total share count, so its effect on EPS or ownership percentages cannot be determined from this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kwo Elizabeth

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/04/2025		A		10,909(1)	A	(1)	10,909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

	/s/ Traci S. Umberger as attorney-in-fact for Elizabeth Kwo	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elizabeth Kwo report on the Form 4 for KMTS?

The Form 4 reports that Elizabeth Kwo acquired 10,909 RSUs on 09/04/2025 which will convert to one common share each upon vesting.

When do the RSUs granted to KMTS director Elizabeth Kwo vest?

The RSUs vest on 09/04/2026 provided the reporting person remains in service through that date.

Was the Form 4 filing for KMTS a sale or a grant?

The filing reports an acquisition of non-derivative securities (RSUs), not a market sale or option exercise.

Who signed the Form 4 for Elizabeth Kwo?

The Form 4 was signed by Traci S. Umberger as attorney-in-fact for Elizabeth Kwo on 09/08/2025.

Does the Form 4 disclose the monetary value or price of the RSU grant?

No. The Form 4 discloses the number of RSUs and vesting date but does not provide a grant price or valuation.